Our observations shed light on the mechanistic basis of how NRF2-activation elicits cancer malignancy and contribute to the understanding of how we could develop NRF2-targeting therapies for NSCLC. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.